Pay in 4 interest-free payments of $7.37 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
37.5% of class 3 obesity entrants exited clinical obesity entirely Waist circumference reduction: -24.1 cm at 12 mg vs -3.6 cm placebo 104 wk extension (n=532, BMI 35 baseline 121.7 kg, BMI 42.8): 12 mg to MTD: -30.3% (-85.0 lbs) 9 mg to MTD: -29.5% (-80.7 lbs) 4 mg to MTD: -27.9% (-73.3 lbs) Placebo to MTD: -19.2% (-49.9 lbs) Cardiometabolic improvements vs placebo: waist circumference, non-HDL cholesterol, triglycerides, systolic BP, hsCRP 4 mg dose: AE-driven discontinuation rate lower than placebo Strategic takeaways: First triple agonist past phase 3, ahead of every competing program TWL distribution closes gap with bariatric surgery (Roux-en-Y ~30%, sleeve ~25%) Pressure on bariatric procedure volumes, PBM utilization management regimes, ICER cost-effectiveness models LLY widens lead over NVO further
It is unclear whether drinking alcohol will impact the effectiveness of semaglutide
Pires M, Rego AC
Join us as we uncover the transformative potential of this groundbreaking therapy
Some people notice appetite changes first, while others see changes in weight or waist measurements later
US$ 22.65
US$ 24.85
US$ 21.99
US$ 28.19
US$ 20.72
